Current status and progress in immunotherapy for malignant pleural mesothelioma
Abstract Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease. Currently, the platinum doublet of pemetrexed and cisplatin is the standard first‐line treatment for unresectable MPM. However, recent promising results of immunotherapy have markedly changed the landscape of M...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | Chronic Diseases and Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cdt3.18 |